Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-05

Study Completion Date

2022-04-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of calcitriol, FGF23 behaves like a hypophosphatemia hormone.

Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets, McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal origin. But more recently, several cases of malignant tumours secreting FGF23 have also been described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FGF-23 Suppressibility by Calcitonin

NCT00688077

Hypophosphatemia

COMPLETED NA

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

NCT03489993

Hypophosphatemia X-linked Hypophosphatemia Renin-angiotensin System +1 more

COMPLETED

A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

NCT01419028

Hypophosphatasia (HPP)

COMPLETED

Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome

NCT01609426

Idiopathic Nephrotic Syndrome

COMPLETED

Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism

NCT02411461

Pseudohypoparathyroidism Albright Hereditary Osteodystrophy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, even if the incidence of FGF23-secreting tumours seems rare, no precise bibliographical data is available in the scientific literature. Future studies will have to address this issue in order not to underestimate the frequency of this complication.

In this context, investigators would like to study the incidence of inappropriate FGF23 increase from a collection of biological samples carried out on 500 patients treated at the Clermont-Ferrand University Hospital for hypophosphatemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypophosphatemia Without Immediate Anteriority Unexplained Hypophosphatemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unexplained hypophosphatemia

Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

unexplained hypophoshatemia

Intervention Type BEHAVIORAL

Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

unexplained hypophoshatemia

Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major patient, male or female
* Taken care of at the Clermont-Ferrand University Hospital or the Jean Perrin Centre
* In a context of hypophosphatemia (\< 0.80 mmol/L), without immediate anteriority and not occurring during hospitalisation
* In capacity to express informed consent to participate in research
* Affiliated to a social security system